** Shares of drug developer Cardiff Oncology CRDF.O fall 32% to $2 premarket

** Cardiff's CEO and CFO both step down, effective immediately

** Co says board member Mani Mohindru appointed as interim CEO while it searches for replacements

** Separately, CRDF says a mid-stage trial showed that adding its experimental drug, onvansertib, to a standard first‑line chemotherapy regimen improved response rates and delayed disease progression in patients with a hard-to-treat form of colorectal cancer

** Says patients who received the higher 30-milligram dose of onvansertib alongside standard chemotherapy had a 72% response rate, compared with 43% for those on standard treatment alone

** Adds that it plans to launch a larger, late-stage trial later this year

** In 2025, CRDF fell 34%

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))